Wolney de Andrade Martins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wolney de Andrade Martins has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
- Antonio José Lagoeiro Jorge
Universidade Federal Fluminense, Brazil
8 shared publications - Humberto Villacorta
Universidade Federal Fluminense, Brasil
8 shared publications - Evandro Tinoco Mesquita
Universidade Federal Fluminense, Brasil; Complexo Hospitalar de Niterói, Brasil
7 shared publications - Claudio Tinoco Mesquita
Universidade Federal Fluminense
6 shared publications - Maria Luiza Garcia Rosa
Universidade Federal Fluminense, Brazil
6 shared publications - Lidia Ana Zytynski Moura
Pontificia Universidade Católica do Parana
5 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (10)
Diretriz Brasileira de Insuficiência Cardíaca – 2026
Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026 Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026
- 7 October 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (10)
Open AccessDiretriz Brasileira de Insuficiência Cardíaca – 2026
Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026 Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026
- Open Access
- 12 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1)
Subclinical Hypothyroidism as a Risk for Coronary Artery Bypass Grafting
Background: The relationship between hypothyroidism and cardiovascular disease is well established. However, data on subclinical hypothyroidism (SH) and its impact on major adverse cardiovascular events (MACEs) and postoperative complications following coronary artery bypass grafting (CABG) remain limited. This study was aimed at evaluating whether SH is associated with an increased risk of these outcomes. Methods: From 2010 to 2019, 863 patients who underwent CABG for cardiovascular diseases at a reference center were included. The primary outcomes included MACE (composite and individual events: all‐cause death, cardiovascular death, stroke, acute myocardial infarction [AMI], and new revascularization) and postoperative complications, including atrial fibrillation (AF), pleural effusion (PLE), pericardial effusion (PCE), infections at any site (IASs), and mediastinitis. Results: SH patients had higher rates of MACE (20.3% vs. 8.2%, p = 0.001), MACE 4p (22.0% vs. 12.9%, p = 0.002), and stroke (10.2% vs. 3.0%, p = 0.013) than those of euthyroid patients. No significant differences were observed in all‐cause death, cardiovascular death, AMI, or new revascularization. Postoperative complications were also more frequent in the SH group: AF (18.6% vs. 9.7%, p = 0.043), PLE (52.6% vs. 19.2%, p < 0.0001), PCE (20.3% vs. 7.8%, p = 0.03), and IAS (28.8% vs. 16.9%, p = 0.032). However, no significant difference was noted in the incidence of mediastinitis. Conclusions: SH patients who underwent CABG had a higher frequency of MACE and postoperative complications than those of euthyroid patients.
- 12 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1)
Open AccessSubclinical Hypothyroidism as a Risk for Coronary Artery Bypass Grafting
Background: The relationship between hypothyroidism and cardiovascular disease is well established. However, data on subclinical hypothyroidism (SH) and its impact on major adverse cardiovascular events (MACEs) and postoperative complications following coronary artery bypass grafting (CABG) remain limited. This study was aimed at evaluating whether SH is associated with an increased risk of these outcomes. Methods: From 2010 to 2019, 863 patients who underwent CABG for cardiovascular diseases at a reference center were included. The primary outcomes included MACE (composite and individual events: all‐cause death, cardiovascular death, stroke, acute myocardial infarction [AMI], and new revascularization) and postoperative complications, including atrial fibrillation (AF), pleural effusion (PLE), pericardial effusion (PCE), infections at any site (IASs), and mediastinitis. Results: SH patients had higher rates of MACE (20.3% vs. 8.2%, p = 0.001), MACE 4p (22.0% vs. 12.9%, p = 0.002), and stroke (10.2% vs. 3.0%, p = 0.013) than those of euthyroid patients. No significant differences were observed in all‐cause death, cardiovascular death, AMI, or new revascularization. Postoperative complications were also more frequent in the SH group: AF (18.6% vs. 9.7%, p = 0.043), PLE (52.6% vs. 19.2%, p < 0.0001), PCE (20.3% vs. 7.8%, p = 0.03), and IAS (28.8% vs. 16.9%, p = 0.032). However, no significant difference was noted in the incidence of mediastinitis. Conclusions: SH patients who underwent CABG had a higher frequency of MACE and postoperative complications than those of euthyroid patients.
- 18 December 2025
- Published by S. Karger AG in Cardiology
- p. 1-15
Diagnosis and Treatment of Right-Sided Valve Disease in Cardiac Carcinoid Syndrome: A Systematic Review
Introduction: Carcinoid heart disease (CaHD) is a severe complication of neuroendocrine tumors, characterized by progressive fibrotic involvement of right-sided heart valves due to serotonin and other vasoactive substances. This condition significantly worsens prognosis and quality of life, yet therapeutic strategies remain heterogeneous and based on low-level evidence. The objective of this study was to systematically review diagnostic approaches and therapeutic options for right-sided valvular disease in CaHD, assessing indications, advantages, limitations, and outcomes. Methods: A systematic review was conducted according to PRISMA guidelines and registered in PROSPERO (CRD42023392363). Searches were performed in PUBMED/MEDLINE, LILACS, and EMBASE for studies published between 2002 and 2024. Eligible studies included clinical trials, observational studies, case series, and case reports evaluating pharmacologic, surgical, or percutaneous interventions for CaHD with reported cardiovascular outcomes. Risk of bias was assessed using ROBINS-I V2 and JBI tools. Results: Of 183 total records, 45 studies met inclusion criteria (30 case reports, 8 case series, 7 observational studies). Tricuspid regurgitation was the most prevalent lesion (90%), followed by pulmonary regurgitation (73%). Somatostatin analogs were frequently used but did not prevent progression of valve disease. Surgical valve replacement, predominantly with bioprostheses, remains the cornerstone for severe symptomatic cases, providing symptomatic and echocardiographic improvement, but with a perioperative mortality of up to 10%. Percutaneous valve therapies, though limited to small series and case reports, demonstrated promising short-term outcomes without major complications. Additional strategies such as patent foramen ovale (PFO) closure and hepatic resection showed potential prognostic benefit. No significant difference in outcomes was observed between biological and mechanical prostheses. Conclusions: Surgical valve replacement remains the most effective evidence-based therapy for CaHD, while percutaneous techniques emerge as feasible alternatives in high-risk patients. Adjunctive measures such as PFO closure and hepatic metastasis resection may improve prognosis. Drug therapies control carcinoid syndrome but are insufficient to halt cardiac disease progression. Further prospective studies are needed to define optimal timing, patient selection, and long-term outcomes of interventional strategies.
- 18 December 2025
- Published by S. Karger AG in Cardiology
- p. 1-15
Diagnosis and Treatment of Right-Sided Valve Disease in Cardiac Carcinoid Syndrome: A Systematic Review
Introduction: Carcinoid heart disease (CaHD) is a severe complication of neuroendocrine tumors, characterized by progressive fibrotic involvement of right-sided heart valves due to serotonin and other vasoactive substances. This condition significantly worsens prognosis and quality of life, yet therapeutic strategies remain heterogeneous and based on low-level evidence. The objective of this study was to systematically review diagnostic approaches and therapeutic options for right-sided valvular disease in CaHD, assessing indications, advantages, limitations, and outcomes. Methods: A systematic review was conducted according to PRISMA guidelines and registered in PROSPERO (CRD42023392363). Searches were performed in PUBMED/MEDLINE, LILACS, and EMBASE for studies published between 2002 and 2024. Eligible studies included clinical trials, observational studies, case series, and case reports evaluating pharmacologic, surgical, or percutaneous interventions for CaHD with reported cardiovascular outcomes. Risk of bias was assessed using ROBINS-I V2 and JBI tools. Results: Of 183 total records, 45 studies met inclusion criteria (30 case reports, 8 case series, 7 observational studies). Tricuspid regurgitation was the most prevalent lesion (90%), followed by pulmonary regurgitation (73%). Somatostatin analogs were frequently used but did not prevent progression of valve disease. Surgical valve replacement, predominantly with bioprostheses, remains the cornerstone for severe symptomatic cases, providing symptomatic and echocardiographic improvement, but with a perioperative mortality of up to 10%. Percutaneous valve therapies, though limited to small series and case reports, demonstrated promising short-term outcomes without major complications. Additional strategies such as patent foramen ovale (PFO) closure and hepatic resection showed potential prognostic benefit. No significant difference in outcomes was observed between biological and mechanical prostheses. Conclusions: Surgical valve replacement remains the most effective evidence-based therapy for CaHD, while percutaneous techniques emerge as feasible alternatives in high-risk patients. Adjunctive measures such as PFO closure and hepatic metastasis resection may improve prognosis. Drug therapies control carcinoid syndrome but are insufficient to halt cardiac disease progression. Further prospective studies are needed to define optimal timing, patient selection, and long-term outcomes of interventional strategies.
- Open Access
- 18 August 2025
- Published by Instituto Nacional de Cardiologia - Brazil in OnScience
- Vol. 3 (2) , e0067
Amiloidose cardíaca associada ao mieloma múltiplo: um desafio diagnóstico na insuficiência cardíaca com fração de ejeção reduzida
O mieloma múltiplo (MM) é uma neoplasia maligna de células B caracterizada pela proliferação clonal de plasmócitos produtores de imunoglobulinas monoclonais. A amiloidose por cadeias leves (AL) é a forma mais comum de amiloidose sistêmica com acometimento cardíaco, associada ao MM em proporção significativa dos casos. O envolvimento cardíaco usualmente cursa com disfunção diastólica e fração de ejeção preservada, porém casos atípicos com disfunção sistólica grave são descritos, representando desafio diagnóstico e terapêutico. Relatamos caso de paciente com MM, insuficiência renal e insuficiência cardíaca com fração de ejeção reduzida, confirmado diagnóstico presuntivo de amiloidose cardíaca AL por biópsia de gordura abdominal positiva e exclusão de amiloidose por transtirretina (ATTR) por cintilografia com pirofosfato. Destacamos a importância da ecocardiografia com strain bidimensional (2D-STI) e da ressonância magnética cardíaca (RMC) no diagnóstico precoce. A integração de métodos clínicos, laboratoriais e imagiológicos é essencial para manejo adequado, especialmente na ausência de espectrometria de massa. O reconhecimento precoce permite intervenção terapêutica e melhora do prognóstico.
- 18 August 2025
- Published by Instituto Nacional de Cardiologia - Brazil in OnScience
- Vol. 3 (2) , e0067
Open AccessAmiloidose cardíaca associada ao mieloma múltiplo: um desafio diagnóstico na insuficiência cardíaca com fração de ejeção reduzida
O mieloma múltiplo (MM) é uma neoplasia maligna de células B caracterizada pela proliferação clonal de plasmócitos produtores de imunoglobulinas monoclonais. A amiloidose por cadeias leves (AL) é a forma mais comum de amiloidose sistêmica com acometimento cardíaco, associada ao MM em proporção significativa dos casos. O envolvimento cardíaco usualmente cursa com disfunção diastólica e fração de ejeção preservada, porém casos atípicos com disfunção sistólica grave são descritos, representando desafio diagnóstico e terapêutico. Relatamos caso de paciente com MM, insuficiência renal e insuficiência cardíaca com fração de ejeção reduzida, confirmado diagnóstico presuntivo de amiloidose cardíaca AL por biópsia de gordura abdominal positiva e exclusão de amiloidose por transtirretina (ATTR) por cintilografia com pirofosfato. Destacamos a importância da ecocardiografia com strain bidimensional (2D-STI) e da ressonância magnética cardíaca (RMC) no diagnóstico precoce. A integração de métodos clínicos, laboratoriais e imagiológicos é essencial para manejo adequado, especialmente na ausência de espectrometria de massa. O reconhecimento precoce permite intervenção terapêutica e melhora do prognóstico.
- Open Access
- 16 February 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (1) , e20230762
Escores para o Diagnóstico da Etiologia Maligna do Derrame Pericárdico: Uma Valiosa Ajuda Inicial na Investigação
Doenças no pericárdio são prevalentes em pacientes com câncer (CA). A presença de derrame pericárdico (DP) nestes pacientes seguramente piora o prognóstico. A possibilidade do tamponamento cardíaco acrescenta risco de morte. O artigo “Testes de Triagem Prevendo Metástase de Câncer na Etiologia do Derrame Pericárdico: HALP Score e PNI” publicado nos ABC Cardiol traz à discussão o dilema clínico da etiologia neoplásica do DP. A facilidade de acesso aos métodos de imagem tornou frequente o diagnóstico do DP nos pacientes
- 16 February 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (1) , e20230762
Open AccessEscores para o Diagnóstico da Etiologia Maligna do Derrame Pericárdico: Uma Valiosa Ajuda Inicial na Investigação
Doenças no pericárdio são prevalentes em pacientes com câncer (CA). A presença de derrame pericárdico (DP) nestes pacientes seguramente piora o prognóstico. A possibilidade do tamponamento cardíaco acrescenta risco de morte. O artigo “Testes de Triagem Prevendo Metástase de Câncer na Etiologia do Derrame Pericárdico: HALP Score e PNI” publicado nos ABC Cardiol traz à discussão o dilema clínico da etiologia neoplásica do DP. A facilidade de acesso aos métodos de imagem tornou frequente o diagnóstico do DP nos pacientes
- Open Access
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7)
Diuretic in Decompensated Heart Failure: With or Without Salt?
Acute or decompensated heart failure (HF) syndrome is a common cause of admission to emergency rooms or HF clinics. Patients often present in profile “B” of the hemodynamic classification and have low therapeutic adherence as the cause of their decompensation. In this clinical situation, the use of high-dose intravenous loop diuretics has been the mainstay of treatment over the last five decades. It does not change the long-term prognosis of the underlying disease, but it moves the patient from the
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7)
Open AccessDiuretic in Decompensated Heart Failure: With or Without Salt?
Acute or decompensated heart failure (HF) syndrome is a common cause of admission to emergency rooms or HF clinics. Patients often present in profile “B” of the hemodynamic classification and have low therapeutic adherence as the cause of their decompensation. In this clinical situation, the use of high-dose intravenous loop diuretics has been the mainstay of treatment over the last five decades. It does not change the long-term prognosis of the underlying disease, but it moves the patient from the
- Open Access
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7) , e20240393
Diurético na Insuficiência Cardíaca Descompensada: Com ou Sem Sal?
A síndrome de insuficiência cardíaca (IC) aguda ou descompensada é causa comum de admissões nas salas de emergências ou clínicas de IC. Frequentemente os pacientes se apresentam em perfil “B” da classificação hemodinâmica e têm na baixa adesão terapêutica a causa de sua descompensação. Nesta situação clínica, o emprego de diurético de alça, venoso, em dose alta, tem sido o pilar do tratamento nas últimas cinco décadas. Não muda o prognóstico da doença de base em longo prazo, mas transloca
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7) , e20240393
Open AccessDiurético na Insuficiência Cardíaca Descompensada: Com ou Sem Sal?
A síndrome de insuficiência cardíaca (IC) aguda ou descompensada é causa comum de admissões nas salas de emergências ou clínicas de IC. Frequentemente os pacientes se apresentam em perfil “B” da classificação hemodinâmica e têm na baixa adesão terapêutica a causa de sua descompensação. Nesta situação clínica, o emprego de diurético de alça, venoso, em dose alta, tem sido o pilar do tratamento nas últimas cinco décadas. Não muda o prognóstico da doença de base em longo prazo, mas transloca
- Open Access
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7)
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024
1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...] 1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7)
Open AccessGuidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024
1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...] 1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis
- Open Access
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7) , e202400415
Diretriz sobre Diagnóstico e Tratamento da Cardiomiopatia Hipertrófica – 2024
1. Introdução O conhecimento médico científico sobre a cardiomiopatia hipertrófica (CMH) recebeu grande avanço nas últimas décadas. O melhor entendimento da sua patogênese, os avanços expressivos no emprego dos métodos de imagem e a aplicação mais corriqueira da análise genética, além da melhor caracterização da história natural dessa doença miocárdica, trouxeram uma profunda reformulação do seu significado clínico e prognóstico. Por outro lado, esses progressos foram acompanhados do desenvolvimento de novas drogas endereçando mecanismos moleculares intrinsecamente ligados à fisiopatogênese da [...] 1. Introdução O conhecimento médico científico sobre a cardiomiopatia hipertrófica (CMH) recebeu grande avanço nas últimas décadas. O melhor entendimento da sua patogênese, os avanços expressivos no emprego dos métodos de imagem e a aplicação mais corriqueira da análise genética, além da melhor caracterização da história natural dessa doença miocárdica, trouxeram uma profunda reformulação do seu significado clínico e prognóstico. Por outro lado, esses progressos foram acompanhados do desenvolvimento de novas drogas endereçando mecanismos moleculares intrinsecamente ligados à fisiopatogênese da
- 1 January 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (7) , e202400415
Open AccessDiretriz sobre Diagnóstico e Tratamento da Cardiomiopatia Hipertrófica – 2024
1. Introdução O conhecimento médico científico sobre a cardiomiopatia hipertrófica (CMH) recebeu grande avanço nas últimas décadas. O melhor entendimento da sua patogênese, os avanços expressivos no emprego dos métodos de imagem e a aplicação mais corriqueira da análise genética, além da melhor caracterização da história natural dessa doença miocárdica, trouxeram uma profunda reformulação do seu significado clínico e prognóstico. Por outro lado, esses progressos foram acompanhados do desenvolvimento de novas drogas endereçando mecanismos moleculares intrinsecamente ligados à fisiopatogênese da [...] 1. Introdução O conhecimento médico científico sobre a cardiomiopatia hipertrófica (CMH) recebeu grande avanço nas últimas décadas. O melhor entendimento da sua patogênese, os avanços expressivos no emprego dos métodos de imagem e a aplicação mais corriqueira da análise genética, além da melhor caracterização da história natural dessa doença miocárdica, trouxeram uma profunda reformulação do seu significado clínico e prognóstico. Por outro lado, esses progressos foram acompanhados do desenvolvimento de novas drogas endereçando mecanismos moleculares intrinsecamente ligados à fisiopatogênese da
- 1 June 2023
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 3 (1)
Toxic Cardiomyopathies: Alcohol, Amphetamines, and Anabolic Steroids
Toxic cardiomyopathies include those caused by drug abuse, as well as chemotherapy agents. This review addresses cardiomyopathies induced by alcoholism, amphetamines, and anabolic steroids, focusing on their pathophysiology, clinical presentation, treatment, and prognosis. Alcoholic cardiomyopathy is frequent and predominates in males. It is dose-dependent, with a probable genetic predisposition. Women are susceptible at lower doses of alcohol intake. The disease ranges from a subclinical asymptomatic form to the typical form of dilated cardiomyopathy with systolic dysfunction and heart failure [...] Abstract Toxic cardiomyopathies include those caused by drug abuse, as well as chemotherapy agents. This review addresses cardiomyopathies induced by alcoholism, amphetamines, and anabolic steroids, focusing on their pathophysiology, clinical presentation, treatment, and prognosis. Alcoholic cardiomyopathy is frequent and predominates in males. It is dose-dependent, with a probable genetic predisposition. Women are susceptible at lower doses of alcohol intake. The disease ranges from a subclinical asymptomatic form to the typical form of dilated cardiomyopathy with systolic dysfunction and heart failure
- 1 June 2023
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 3 (1)
Toxic Cardiomyopathies: Alcohol, Amphetamines, and Anabolic Steroids
Toxic cardiomyopathies include those caused by drug abuse, as well as chemotherapy agents. This review addresses cardiomyopathies induced by alcoholism, amphetamines, and anabolic steroids, focusing on their pathophysiology, clinical presentation, treatment, and prognosis. Alcoholic cardiomyopathy is frequent and predominates in males. It is dose-dependent, with a probable genetic predisposition. Women are susceptible at lower doses of alcohol intake. The disease ranges from a subclinical asymptomatic form to the typical form of dilated cardiomyopathy with systolic dysfunction and heart failure [...] Abstract Toxic cardiomyopathies include those caused by drug abuse, as well as chemotherapy agents. This review addresses cardiomyopathies induced by alcoholism, amphetamines, and anabolic steroids, focusing on their pathophysiology, clinical presentation, treatment, and prognosis. Alcoholic cardiomyopathy is frequent and predominates in males. It is dose-dependent, with a probable genetic predisposition. Women are susceptible at lower doses of alcohol intake. The disease ranges from a subclinical asymptomatic form to the typical form of dilated cardiomyopathy with systolic dysfunction and heart failure